Method for treating diabetes and other glucose regulation disorders using stem cells
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10398737-B2
Publication Date
2019-09-03
Expiration Date
Abstract
Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.
Core Innovation
The invention relates to a method for treating diabetes by generating stem cell-derived hormone producing-cells (SCDHPC) from patient stem cells in co-culture with donor gastrointestinal hormone producing cells. The donor gastrointestinal hormone producing cells are incretin-producing cells, where the gastrointestinal hormone is an incretin that regulates glucose in the body of a human.
The method includes obtaining gastrointestinal hormone producing cells from a donor and obtaining stem cells from a patient. The gastrointestinal hormone producing cells are cultured in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived hormone producing-cells (SCDHPC), and an amount of the SCDHPC is introduced into the patient to lower blood glucose after ingestion of food or to maintain blood glucose within euglycemic levels for an extended period.
The disclosed approach is directed to stem cell-derived L-cell mimics (SCDLC producing GLP-1) or stem cell-derived K-cell mimics (SCDKC producing GIP) derived from co-culturing autologous stem cells with donor gastrointestinal endocrine cells. Differentiated cells are introduced into intestinal submucosa to reseed and secrete incretins upon stimulation by nutrients such as carbohydrates, fats, glucose, and fatty acids.
Claims Coverage
The document provides two independent claims, both centered on culturing donor gastrointestinal hormone producing cells with patient stem cells to form SCDHPC and introducing the SCDHPC into the patient to improve glucose regulation. Across the two independent claims, the inventive features focus on donor-derived incretin-producing gastrointestinal hormone producing cells, patient-derived stem cells differentiating into SCDHPC, and administration to achieve blood glucose lowering after food ingestion or maintenance within euglycemic levels for an extended period.
Incretin-producing gastrointestinal hormone producing cells co-cultured with patient stem cells to form SCDHPC
Obtaining gastrointestinal hormone producing cells from a donor, wherein said gastrointestinal hormone regulates glucose in the body of a human; obtaining stem cells from a patient; culturing the gastrointestinal hormone producing cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived hormone producing-cells (SCDHPC); and wherein the gastrointestinal hormone producing cells are incretin-producing cells and wherein the gastrointestinal hormone is an incretin.
Blood glucose lowering after food ingestion by introducing SCDHPC
Introducing an amount of the SCDHPC into the patient sufficient to cause a lowering of the patient's blood glucose level after the ingestion of food, wherein the gastrointestinal hormone producing cells are incretin-producing cells and wherein the gastrointestinal hormone is an incretin.
Extended euglycemic maintenance by introducing SCDHPC
Introducing an amount of the SCDHPC into the patient sufficient to maintain the patient's blood glucose levels within euglycemic levels for an extended period, wherein the gastrointestinal hormone producing cells are incretin-producing cells and wherein the gastrointestinal hormone is an incretin.
Both independent claims require culturing donor incretin-producing gastrointestinal hormone producing cells with patient stem cells to generate SCDHPC, followed by introduction of SCDHPC into the patient. One independent claim targets blood glucose lowering after food ingestion, while the other targets maintaining blood glucose within euglycemic levels for an extended period.
Stated Advantages
Lowering the patient’s blood glucose level after ingestion of food.
Maintaining the patient’s blood glucose levels within euglycemic levels for an extended period.
Documented Applications
Treating diabetes in a human using stem cell-derived incretin-producing hormone producing-cells (SCDHPC) generated by culturing donor gastrointestinal hormone producing cells with patient stem cells.
Interested in licensing this patent?